Drug Development Team
William D. Kerns, DVM, MS, DACVP
VP Drug Development
Dr. Kerns has over 20 years of experience in pharmaceutical research and development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in the development of drugs for over 100 Phase I studies and 13 NDAs/MAAs. Dr. Kerns has chaired a U.S. FDA committee on biomarkers, and he is an expert in preclinical development and regulatory strategy.
Dr. Kerns received a doctorate from The Ohio State University College of Veterinary Medicine and an undergraduate degree from The Ohio State University.
Michael Silverman, MD
Dr. Silverman has extensive experience in clinical development acquired through his work at large pharmaceutical and small biopharmaceutical companies. He was involved in international clinical research, market-oriented strategic planning, and managed an R&D portfolio in various capacities at Sterling Winthrop Research Institute and subsequently at Sandoz Research Institute.
Zivit Harpaz, MA
Director of Regulatory and Clinical Operations
Ms. Harpaz earned her M.A. at Haifa University, Israel. She has over 15 years of experience in clinical trial management where she led the logistical, regulatory and clinical monitoring affairs of Phase I/II, Phase II and Phase III clinical studies in the fields of oncology, ophthalmology, autoimmune inflammatory and metabolic diseases.